Mondego Bio doses first humans with oral MB-388, an immunotherapy-resistance drug targeting the PTPN2/PTPN1 pathway. Phase 1a data expected December 2026.

Cork startup ArrayPatch builds dissolving microneedles entirely from the drug itself — no polymer — and may put GLP-1 obesity ...

New patient experience dataa to be presented at ACR 2026 show mouth dryness was reported as the most important symptom to improve, followed by eye dryness, fatigue and ...

For pharmacists, physicians, and nurses handling anti-MRSA drugs in the ICU, we have summarized the key points for vancomycin ...

Mouse toxicity findings and insufficient juvenile-toxicity data led the FDA to place Bright Minds Biosciences' (NASDAQ: DRUG) ...

Shareholders of Bright Minds Biosciences (NASDAQ: DRUG) are holding losses after the stock sold off when the FDA placed the ...

A review in Molecular Cancer examines how antibody-drug conjugates treat solid tumors while addressing clinical resistance, ...

Drs. Haydon DuMond, Mehul Desai, and Shirish Ingawale examine research findings and regulatory precedents demonstrating that ...

Collaboration with Imperial College London and City St George’s, University of London combines £2.1 million in MRC ...

Bright Minds Biosciences’ further studies or protocol changes could become a path past the FDA’s recent hold decision. Read ...

NorthSea Therapeutics B.V. (“NorthSea” or the “Company”) is a private, late-stage clinical biotechnology company leveraging its proprietary SEFA™ platform to develop novel drugs addressing the ...

A CMS final rule codifies Medicare drug price negotiation from 2029, adds a fixed combination drug policy and implements a small biotech price floor.